LetterThirty-day Mortality for Patients with Genitourinary Malignancies Being Treated with Chemotherapy
References (2)
For better, for worse?
- et al.
Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer
N Engl J Med
(2004)
Cited by (5)
A population-based study of prostate cancer chemotherapy
2011, Clinical OncologyCitation Excerpt :Many prostate cancer patients are unfit for chemotherapy, the NICE guidance stipulating that a patient must be of good performance status to receive docetaxel [5]. There is evidence to suggest that in this patient group, a poor performance status is associated with higher rates of 30 day mortality after chemotherapy [6]. In addition, some patients choose not to receive chemotherapy, so overall it is uncertain to what extent patients are ‘missing out’ on treatment.
Targeted nanomedicine to treat bone metastasis
2018, PharmaceuticsMortality within 30days of receiving systemic anti-cancer therapy at a regional oncology unit: What have we learned?
2012, Asia-Pacific Journal of Clinical Oncology
Copyright © 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.